Citigroup Inc Chinook Therapeutics, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$18.66 - $38.58 $806,802 - $1.67 Million	-43,237 Reduced 29.25%	104,573 $4.02 Million
Q1 2023 May 11, 2023	BUY	$21.53 - $26.8 $1.5 Million - $1.87 Million	69,615 Added 89.03%	147,810 $3.42 Million
Q4 2022 Feb 09, 2023	SELL	$18.63 - $27.35 $1 Million - $1.47 Million	-53,812 Reduced 40.76%	78,195 $2.05 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $1.54 Million - $2.05 Million	87,710 Added 198.0%	132,007 $2.6 Million
Q2 2022 Aug 10, 2022	BUY	$12.59 - $18.8 $370,863 - $553,791	29,457 Added 198.5%	44,297 $775,000
Q1 2022 May 12, 2022	SELL	$12.02 - $16.69 $540,912 - $751,066	-45,001 Reduced 75.2%	14,840 $243,000
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $266,790 - $420,026	24,957 Added 71.54%	59,841 $976,000
Q3 2021 Nov 10, 2021	BUY	$11.5 - $14.86 $401,166 - $518,376	34,884 New	34,884 $445,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.